BMS-986504

DRUG8 trials

Sponsors

Bristol-Myers Squibb, Nader Sanai, M.D. Anderson Cancer Center

Conditions

Advanced Solid TumorsAdvanced Solid Tumors With Homozygous MTAP DeletionBMS-986504Carcinoma, Non-Small-Cell LungGlioblastoma WHO Grade IVMTAP-deleted Pancreatic CancerMetastatic Non-small Cell Lung Cancer With MTAP DeletionPancreatic Ductal Adenocarcinoma

Early Phase 1

Clinical Trial of BMS-986504 in Recurrent GBM Patients

RecruitingNCT06883747

Nader SanaiGlioblastoma WHO Grade IV

Start: 2025-04-28End: 2027-09-28Target: 9Updated: 2025-06-19

Phase 1

A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion

RecruitingNCT06672523

Bristol-Myers SquibbAdvanced Solid Tumors With Homozygous MTAP Deletion

Start: 2025-03-24End: 2026-04-20Target: 8Updated: 2025-04-11

A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors

RecruitingNCT07077434

Bristol-Myers SquibbAdvanced Solid Tumors

Start: 2025-10-15End: 2027-01-19Target: 32Updated: 2026-01-05

Phase 2

A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

RecruitingNCT06855771

Bristol-Myers SquibbCarcinoma, Non-Small-Cell Lung

Start: 2025-09-09End: 2031-12-30Target: 130Updated: 2026-03-24

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

RecruitingNCT07063745

Bristol-Myers SquibbMetastatic Non-small Cell Lung Cancer With MTAP Deletion

Start: 2026-01-02End: 2031-08-12Target: 590Updated: 2026-03-17

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

RecruitingNCT07076121

Bristol-Myers SquibbPancreatic Ductal Adenocarcinoma

Start: 2025-10-23End: 2029-05-03Target: 470Updated: 2026-03-31

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

SuspendedNCT07283705

M.D. Anderson Cancer CenterBMS-986504, MTAP-deleted Pancreatic Cancer, Phase 2 Study

Start: 2026-05-18End: 2031-10-01Target: 60Updated: 2026-03-18

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Not yet recruitingNCT07492680

Bristol-Myers SquibbSolid Tumors

Start: 2026-07-17End: 2032-05-20Target: 260Updated: 2026-03-25

Related Papers

A phase 2/3 randomized study of BMS-986504 with nab-paclitaxel (nab-P) and gemcitabine (GEM) in first-line (1L) metastatic pancreatic ductal adenocarcinoma (PDAC) with homozygous <i>MTAP</i> deletion ( <i>MTAP</i> -del): MountainTAP-30.

Journal of Clinical Oncology2026-01-10

TIP-09. A phase 0/1 study of PRMT5 inhibitor BMS-986504 in recurrent glioblastoma participants with MTAP deletion

Neuro-Oncology2025-11-01

P12.27.B A PHASE 0/1 STUDY OF PRMT5 INHIBITOR BMS-986504 IN RECURRENT GLIOBLASTOMA PARTICIPANTS WITH MTAP DELETED TUMORS.

Neuro-Oncology2025-10-01